Nexavar (sorafenib), which had been leading the liver cancer treatment market for over 10 years since its launch, has handed over its lead to ‘Lenvima (lenvatinib)’.

This was a combined result of Nexavar’s drug price falling 30% due to the launch of its generics, and the rise in sales of its competitor Lenvima.

Nexavar’s position in the liver cancer treatment market is expected to shrink further while competing with its generics as more products awaiting to enter the market.

◆1H sales of Nexavar drop from ₩10.3 billion to ₩5.6 billion… Impact of drug price cut

According to the pharmaceutical market research firm IQVIA on the 28th, Bay